ICR and Royal Marsden investigator team

New Capabilities

Contributing trial center; presenting co-authors at ESMO 2026

An experimental Johnson & Johnson combination shrank tumors in 77% of patients with a hard-to-treat form of advanced head and neck cancer, more than double the 36% response rate of the current first-line standard. The results came from 22 patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma and were presented at the European Society for Medical Oncology congress in Madrid on October 25.

Updated 2 hours ago